Overview

ONO-5920/YM529 Confirmatory Study in Involutional Osteoporosis Patients

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
This is a multi-center double-blind parallel-group study in involutional osteoporosis patients to compare the efficacy and safety of monthly oral intermittent formulation ONO-5920/YM529 with its daily formulation.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
Ono Pharmaceutical Co. Ltd
Treatments:
Diphosphonates